The type 2 diabetes therapy market will steadily expand over the 2019-2029 study period, fueled by increasing prevalence and high unmet need for drugs that can effectively control the disease in the long term. A rich pipeline of novel agents is expected to launch, promoting sustained market growth. However, these novel therapies predominantly represent later-to-market entrants from existing drug classes or novel combination therapies of existing compounds. Among the drug classes expected to undergo the fastest growth are the sodium/glucose cotransporter 2 (SGLT 2) inhibitors—due to the cardiovascular (CV) benefit demonstrated by Jardiance—and the glucagon-like peptide 1 (GLP 1) receptor agonists—due to their efficacy, potential for weight loss, and the CV benefit associated with Victoza and Ozempic. However, these therapies will face major challenges in uptake, including reimbursement hurdles and an increasingly stringent regulatory environment.
- Following Jardiance’s positive CV results, will SGLT 2 inhibitors surpass the dipeptidyl peptidase (DPP) IV inhibitors as the most valuable oral drug class?
- Boosted by positive CV data, will Victoza continue to lead the GLP 1 receptor agonists in the face of once-weekly agents such as Trulicity and Ozempic?
- Will investments by the pharmaceutical industry in novel FDCs such as Xultophy and Soliqua reap rewards?
- What do key opinion leaders think about emerging therapies such as sotagliflozin, ITCA-650, and oral semaglutide?
- United States, EU5, Japan
- 19 country-specific interviews with thought-leading endocrinologists and diabetologists. Supported by survey data collected for this and other DRG research
- Prevalence of T2D by country with population-specific diagnosed and drug-treatment rates
- 10-year, annualized, drug-level sales and patient share of key T2D therapies through 2029, segmented by brands/generics
- Phase III/PR: 7 drugs; coverage of select preclinical, Phase I, and Phase II products
- Type 2 Diabetes - Landscape & Forecast - Disease Landscape & Forecast
Author(s): David Rees, Ph.D; Joseph Granato, MPH
David Rees, M.Biochem., Ph.D, is a Business Insights Analyst with the Cardiovascular, Metabolic, and Renal Disorders team at Decision Resources Group. Prior to joining Decision Resources Group, Dr. Rees was a Postdoctoral Research Associate at Imperial College London, and the Institute of Cancer Research. For his doctoral research, he studied the structures of molecular machines in the Nobel Prize winning laboratory of Prof. Sir John Walker at the University of Cambridge. Dr. Rees earned his undergraduate M.Biochem. from the University of Bath.
Joseph Granato joined Decision Resources Group in 2012 and previously worked on both Market Access and Global Market Access products. Joseph is currently responsible for forecasting the prevalence and incidence of disease populations throughout the world. He is also tasked with identifying at risk populations and developing new epidemiological methods used to predict overall population health.
He received his M.P.H. from Des Moines University where he worked on several population health projects including the delivery of continuing medical education on tick-borne diseases. He also holds a B.S. in Animal Science from the University of Tennessee. Prior to his time with DRG Joseph worked with the Monroe County Health Department on the surveillance of reportable diseases including Dengue Fever.